Paul T. Thevenot, Ph.D.
Affiliations: | 2010 | Biomedical Engineering | University of Texas at Arlington, Arlington, TX, United States |
Area:
Biomedical Engineering, ImmunologyGoogle:
"Paul Thevenot"Parents
Sign in to add mentor| Liping Tang | grad student | 2010 | UT Arlington | |
| (Mechanisms of biomaterial mediated fibrotic responses and strategies to improve tissue reactions to biomaterial implants.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Mohamed E, Sierra RA, Trillo-Tinoco J, et al. (2020) The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 52: 668-682.e7 |
| Truong T, Ramalingam V, Morris T, et al. (2020) 3:54 PM Abstract No. 233 Immune status correlates with locoregional treatment response, new tumor development, and tumor necrosis in patients with hepatocellular carcinoma Journal of Vascular and Interventional Radiology. 31 |
| Sandow T, Nunez K, Gimenez J, et al. (2019) 03:45 PM Abstract No. 213 Synthetic liver function and absolute lymphocyte count are associated with tumor response to locoregional therapy as well as immunosuppressive cell populations in transplant waitlist patients with hepatocellular carcinoma: single-center, prospective, observational trial Journal of Vascular and Interventional Radiology. 30 |
| Nunez KG, Sandow T, Robertson S, et al. (2019) Liver functional reserve and pre-treatment immune tolerance in waitlist treatment naïve HCC patients is associated with poor tumor response to locoregional therapy Hpb. 21 |
| Sandow TA, Arndt SE, Albar AA, et al. (2017) Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort. Radiology. 170731 |
| Raber PL, Sierra RA, Thevenot PT, et al. (2016) T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy. Oncotarget |
| Fletcher M, Ramirez ME, Sierra RA, et al. (2015) l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Research. 75: 275-83 |
| Raber P, Thevenot P, Sierra R, et al. (2015) Antigen-specific T cells conditioned with MDSC display a surprising increased anti-tumor activity after adoptive T cell-based immunotherapy Journal For Immunotherapy of Cancer. 3: P413 |
| Thevenot PT, Sierra RA, Raber PL, et al. (2014) The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity. 41: 389-401 |
| Sierra RA, Thevenot P, Raber PL, et al. (2014) Rescue of notch-1 signaling in antigen-specific CD8+ T cells overcomes tumor-induced T-cell suppression and enhances immunotherapy in cancer. Cancer Immunology Research. 2: 800-11 |